NRx Pharmaceuticals announced that its Board of Directors has authorized its Chairman and management to take all necessary steps to affect a dividend of HOPE Therapeutics stock along with a royalty right of 1% of Ketamine sales to NRXP Shareholders and applicable warrant holders. The intent of the Board is to distribute 49% of HOPE stock in this dividend. Shares of HOPE are planned to be publicly listed. Instructions and further details will be communicated through the company’s website and usual channels as they become available.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on NRXP:
- NRx Pharmaceuticals (NASDAQ:NRXP) Announces Plan to Distribute Shares of HOPE Therapeutics and Royalty Rights on Ketamine Sales to Existing NRx Shareholders
- NRx Pharmaceuticals initiates strategy to combat short sales
- NRx Pharmaceuticals completes MOU with distribution partners for HTX-100
- NRx Pharmaceuticals: Last patient, last visit in Phase 2b/3 trial of NRX-101
- NRx Pharmaceuticals announces $1M purchase agreement
